🚀 VC round data is live in beta, check it out!
Eikon Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Eikon Therapeutics and similar public comparables like Prime Medicine, Tempo Scan Pacific, Jade Biosciences, Blue Jet Healthcare and more.
Eikon Therapeutics Overview
About Eikon Therapeutics
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.
Founded
2019
HQ
Employees
384
Website
Financials (LTM)
EV
$608M
Eikon Therapeutics Financials
Eikon Therapeutics reported last 12-month revenue of — and negative EBITDA of ($340M).
In the same LTM period, Eikon Therapeutics generated — in gross profit, ($340M) in EBITDA losses, and had net loss of ($339M).
Eikon Therapeutics P&L
In the most recent fiscal year, Eikon Therapeutics reported revenue of — and EBITDA of ($218M).
Eikon Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($340M) | XXX | ($218M) | XXX | XXX | XXX |
| Net Profit | ($339M) | XXX | ($244M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Eikon Therapeutics Stock Performance
Eikon Therapeutics has current market cap of $743M, and enterprise value of $608M.
Eikon Therapeutics' stock price is $13.77.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $608M | $743M | 0.0% | XXX | XXX | XXX | $-4.52 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialEikon Therapeutics Valuation Multiples
Eikon Therapeutics trades at (1.8x) EV/EBITDA.
Eikon Therapeutics Financial Valuation Multiples
As of March 29, 2026, Eikon Therapeutics has market cap of $743M and EV of $608M.
Equity research analysts estimate Eikon Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Eikon Therapeutics has a P/E ratio of (2.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $743M | XXX | $743M | XXX | XXX | XXX |
| EV (current) | $608M | XXX | $608M | XXX | XXX | XXX |
| EV/EBITDA | (1.8x) | XXX | (2.8x) | XXX | XXX | XXX |
| EV/EBIT | (1.7x) | XXX | (2.3x) | XXX | XXX | XXX |
| P/E | (2.2x) | XXX | (3.0x) | XXX | XXX | XXX |
| EV/FCF | (1.9x) | XXX | (2.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Eikon Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Eikon Therapeutics Margins & Growth Rates
Eikon Therapeutics' revenue in the last fiscal year grew by —.
Eikon Therapeutics' revenue per employee in the last FY averaged $0.0M.
Eikon Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 15% | XXX | 50% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Eikon Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Life Sciences Tools comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Prime Medicine | XXX | XXX | XXX | XXX | XXX | XXX |
| Tempo Scan Pacific | XXX | XXX | XXX | XXX | XXX | XXX |
| Jade Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Blue Jet Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Kura Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Eikon Therapeutics M&A Activity
Eikon Therapeutics acquired XXX companies to date.
Last acquisition by Eikon Therapeutics was on XXXXXXXX, XXXXX. Eikon Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Eikon Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialEikon Therapeutics Investment Activity
Eikon Therapeutics invested in XXX companies to date.
Eikon Therapeutics made its latest investment on XXXXXXXX, XXXXX. Eikon Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Eikon Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Eikon Therapeutics
| When was Eikon Therapeutics founded? | Eikon Therapeutics was founded in 2019. |
| Where is Eikon Therapeutics headquartered? | Eikon Therapeutics is headquartered in United States. |
| How many employees does Eikon Therapeutics have? | As of today, Eikon Therapeutics has over 384 employees. |
| Is Eikon Therapeutics publicly listed? | Yes, Eikon Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Eikon Therapeutics? | Eikon Therapeutics trades under EIKN ticker. |
| When did Eikon Therapeutics go public? | Eikon Therapeutics went public in 2026. |
| Who are competitors of Eikon Therapeutics? | Eikon Therapeutics main competitors are Prime Medicine, Tempo Scan Pacific, Jade Biosciences, Blue Jet Healthcare. |
| What is the current market cap of Eikon Therapeutics? | Eikon Therapeutics' current market cap is $743M. |
| Is Eikon Therapeutics profitable? | No, Eikon Therapeutics is not profitable. |
| What is the current EBITDA of Eikon Therapeutics? | Eikon Therapeutics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Eikon Therapeutics? | Current EBITDA multiple of Eikon Therapeutics is (1.8x). |
| What is the current FCF of Eikon Therapeutics? | Eikon Therapeutics' last 12 months FCF is ($313M). |
| What is the current EV/FCF multiple of Eikon Therapeutics? | Current FCF multiple of Eikon Therapeutics is (1.9x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.